{"id":"rfix-r","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"rFIX-R works by replacing the missing or defective factor IX in patients with hemophilia B, allowing for proper blood clotting and stopping bleeding episodes. This is particularly useful for patients who have developed antibodies against previous factor IX treatments, making it difficult to find an effective replacement therapy.","oneSentence":"rFIX-R is a recombinant coagulation factor IX used to treat bleeding episodes in patients with hemophilia B.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:58.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of bleeding episodes in patients with hemophilia B"},{"name":"Prevention of bleeding in patients with hemophilia B undergoing surgery"}]},"trialDetails":[{"nctId":"NCT02392156","phase":"","title":"Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes","status":"TERMINATED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2015-07","conditions":"Hemophilia A, Hemophilia B","enrollment":3},{"nctId":"NCT00364182","phase":"PHASE3","title":"Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-05","conditions":"Hemophilia B","enrollment":50},{"nctId":"NCT00093210","phase":"PHASE3","title":"Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Hemophilia B","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rFIX-R","genericName":"rFIX-R","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rFIX-R is a recombinant coagulation factor IX used to treat bleeding episodes in patients with hemophilia B. Used for Treatment of bleeding episodes in patients with hemophilia B, Prevention of bleeding in patients with hemophilia B undergoing surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}